146 related articles for article (PubMed ID: 21647141)
1. A CUE hints at tumor resistance.
Thomas C; Gustafsson JA
Nat Med; 2011 Jun; 17(6):658-60. PubMed ID: 21647141
[No Abstract] [Full Text] [Related]
2. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.
Pan X; Zhou T; Tai YH; Wang C; Zhao J; Cao Y; Chen Y; Zhang PJ; Yu M; Zhen C; Mu R; Bai ZF; Li HY; Li AL; Liang B; Jian Z; Zhang WN; Man JH; Gao YF; Gong WL; Wei LX; Zhang XM
Nat Med; 2011 Jun; 17(6):708-14. PubMed ID: 21572428
[TBL] [Abstract][Full Text] [Related]
3. ERasing breast cancer resistance through the kinome.
Johnson AB; O'Malley BW
Nat Med; 2011 Jun; 17(6):660-1. PubMed ID: 21647142
[No Abstract] [Full Text] [Related]
4. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
5. Role of endothelin-1 in tamoxifen resistance: Mechanism for a new possible treatment strategy in breast cancer.
Namazi S; Rouhani Fard SA; Abedtash H
Med Hypotheses; 2008; 70(1):109-11. PubMed ID: 17576039
[TBL] [Abstract][Full Text] [Related]
6. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
7. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
8. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.
Chan CM; Lykkesfeldt AE; Parker MG; Dowsett M
Clin Cancer Res; 1999 Nov; 5(11):3460-7. PubMed ID: 10589759
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
10. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Schiff R; Osborne CK
Breast Cancer Res; 2005; 7(5):205-11. PubMed ID: 16168139
[TBL] [Abstract][Full Text] [Related]
11. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
[TBL] [Abstract][Full Text] [Related]
12. Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models.
Gee JM; Hutcheson IR
Breast Cancer Res; 2005; 7(5):187-9. PubMed ID: 16168136
[No Abstract] [Full Text] [Related]
13. RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy.
Witkiewicz AK; Knudsen ES
Cell Cycle; 2011 May; 10(10):1525. PubMed ID: 21502809
[No Abstract] [Full Text] [Related]
14. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
[TBL] [Abstract][Full Text] [Related]
15. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
Osborne CK; Schiff R
Breast; 2003 Dec; 12(6):362-7. PubMed ID: 14659106
[TBL] [Abstract][Full Text] [Related]
16. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
17. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
Higgins MJ; Stearns V
Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
[No Abstract] [Full Text] [Related]
18. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Zhao H; Ou-Yang F; Chen IF; Hou MF; Yuan SS; Chang HL; Lee YC; Plattner R; Waltz SE; Ho SM; Sims J; Wang SC
Neoplasia; 2010 Mar; 12(3):214-23. PubMed ID: 20234815
[TBL] [Abstract][Full Text] [Related]
19. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.
De Marchi T; Kuhn E; Dekker LJ; Stingl C; Braakman RB; Opdam M; Linn SC; Sweep FC; Span PN; Luider TM; Foekens JA; Martens JW; Carr SA; Umar A
J Proteome Res; 2016 Apr; 15(4):1230-42. PubMed ID: 26958999
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor degradation: a CUE for endocrine resistance?
Musgrove EA
Breast Cancer Res; 2011 Aug; 13(4):312. PubMed ID: 21861853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]